JAC Advance Access originally published online on December 2, 2005
Journal of Antimicrobial Chemotherapy 2006 57(2):279-287; doi:10.1093/jac/dki437
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Oxazolidinone susceptibility patterns in 2004: report from the Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations
1 JMI Laboratories, Inc., 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA; 2 Tufts University School of Medicine, 136 Harrison Avenue, Boston, MA 02111, USA
Received 8 September 2005; returned 27 October 2005; revised 3 November 2005; accepted 6 November 2005
* Corresponding author. Tel: +1-319-665-3370; Fax: +1-319-665-3371; E-mail: ronald-jones{at}jmilabs.com
Objectives: To investigate the activity of linezolid (an oxazolidinone), a potent choice for community- and hospital-acquired infections, via a worldwide surveillance network called the Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) Program.
Methods: A total of 4098 Gram-positive strains were collected from 42 laboratories located in North America (five sites in Canada), South America (10 sites), Europe (16 sites) and the Far East (11 sites). Each country or site submitted 200 isolates (Canada submitted 200 isolates for each of five sites; total 1000) for confirmation of organism identification and reference MIC processing. Nearly 25 comparator agents were tested along with quality control strains, and interpretative criteria from the CLSI, formerly the NCCLS, M100-S15 were applied. No linezolid resistance was detected in strains from 16 monitored countries in 2004.
Results: Linezolid remained highly active against Streptococcus pneumoniae, viridans group and ß-haemolytic streptococci (MIC90, 1 mg/L). Against Staphylococcus aureus, linezolid showed 99.5% of results at 0.5–2 mg/L with only one isolate at 4 mg/L. Oxacillin-resistant S. aureus rates varied between nations and ranged from 1.4% in Sweden to 29.5% in the UK to 65.2% in Mexico. Linezolid MIC values were generally one log2 dilution step lower for coagulase-negative staphylococci (CoNS) when compared with S. aureus. No CoNS strains produced a linezolid result at 4 mg/L. Compared with ZAAPS 2002 and 2003 results for enterococci where seven resistant strains were identified, the 2004 data revealed no resistance and 98.1% of linezolid MIC results were at 1 or 2 mg/L. Vancomycin-resistant enterococci (5.3% overall) varied markedly by country including a high of 47.2% in Korea.
Conclusions: Linezolid continues to be effective in vitro against Gram-positive pathogens from five continents and no oxazolidinone-resistant strains were identified among the 4098 systemically collected strains (2004) or among 20 158 non-United States isolates for the entire ZAAPS Program (2002–04).
Keywords: linezolid , MRSA , VRE , surveillance
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. Skripkin, T. S. McConnell, J. DeVito, L. Lawrence, J. A. Ippolito, E. M. Duffy, J. Sutcliffe, and F. Franceschi R{chi}-01, a New Family of Oxazolidinones That Overcome Ribosome-Based Linezolid Resistance Antimicrob. Agents Chemother., October 1, 2008; 52(10): 3550 - 3557. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Lawrence, P. Danese, J. DeVito, F. Franceschi, and J. Sutcliffe In Vitro Activities of the Rx-01 Oxazolidinones against Hospital and Community Pathogens Antimicrob. Agents Chemother., May 1, 2008; 52(5): 1653 - 1662. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kelly, J. Collins, M. Maguire, C. Gowing, M. Flanagan, M. Donnelly, and P. G. Murphy An outbreak of colonization with linezolid-resistant Staphylococcus epidermidis in an intensive therapy unit J. Antimicrob. Chemother., April 1, 2008; 61(4): 901 - 907. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Tsakris, S. K. Pillai, H. S. Gold, C. Thauvin-Eliopoulos, L. Venkataraman, C. Wennersten, R. C. Moellering Jr, and G. M. Eliopoulos Persistence of rRNA operon mutated copies and rapid re-emergence of linezolid resistance in Staphylococcus aureus J. Antimicrob. Chemother., September 1, 2007; 60(3): 649 - 651. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Soriano, M. Ortega, S. Garcia, G. Penarroja, A. Bove, M. Marcos, J. C. Martinez, J. A. Martinez, and J. Mensa Comparative Study of the Effects of Pyridoxine, Rifampin, and Renal Function on Hematological Adverse Events Induced by Linezolid Antimicrob. Agents Chemother., July 1, 2007; 51(7): 2559 - 2563. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. N. Jones, M. G. Stilwell, P. A. Hogan, and D. J. Sheehan Activity of Linezolid against 3,251 Strains of Uncommonly Isolated Gram-Positive Organisms: Report from the SENTRY Antimicrobial Surveillance Program Antimicrob. Agents Chemother., April 1, 2007; 51(4): 1491 - 1493. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kelly, J. Collins, M. Davin, C. Gowing, and P. G. Murphy Linezolid resistance in coagulase-negative staphylococci1 J. Antimicrob. Chemother., October 1, 2006; 58(4): 898 - 899. [Full Text] [PDF]
|
|
|
|
|
|
R. N. Jones, J. E. Ross, T. R. Fritsche, and H. S. Sader Comment on: Linezolid resistance in coagulase-negative staphylococci2 J. Antimicrob. Chemother., October 1, 2006; 58(4): 899 - 900. [Full Text] [PDF]
|
|
|
|
|
|
L. Vera-Cabrera, E. Gonzalez, A. Rendon, J. Ocampo-Candiani, O. Welsh, V. M. Velazquez-Moreno, S. Hak Choi, and C. Molina-Torres In Vitro Activities of DA-7157 and DA-7218 against Mycobacterium tuberculosis and Nocardia brasiliensis. Antimicrob. Agents Chemother., September 1, 2006; 50(9): 3170 - 3172. [Abstract] [Full Text] [PDF]
|
|